• Je něco špatně v tomto záznamu ?

The Effect of Flubendazole on Adhesion and Migration in SW480 and SW620 Colon Cancer Cells

V. Hanušová, L. Skálová, V. Králová, P. Matoušková,

. 2018 ; 18 (6) : 837-846. [pub] -

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035479

BACKGROUND: Colon cancer is the most common type of gastrointestinal cancer. Despite advances during the last two decades, the efficacy of colorectal cancer treatment is still insufficient and new anticancer agents are necessary. METHODS: In our study, colon cancer cells derived from a primary tumor (SW480) and lymph node metastasis (SW620) from the same patient were used and compared. The effect of flubendazole (FLU) on cell adhesion and migration was monitored using the x-CELLigence Real-Time Cell Analysis system. Expressions of molecules involved in adhesion and migration were analyzed using RT-PCR and western blot. Furthermore, RNA silencing of nuclear factor-κB in SW620 cells was used to determine the involvement of the NF-κB p65 regulation pathway in FLU action. RESULTS: FLU significantly suppressed the adhesion of SW480 cells and reduced the expression of adhesion markers (ICAM-1, αE-catenin; β-catenin; integrin α5 and β1). Moreover, a significant anti-migratory potential of FLU was manifested in the SW620 cells. In addition, FLU suppressed the phosphorylation of NF-κB p65 and potentiated the suppression of several metastatic markers (ICAM-1, EpCAM, integrin α5, β1, α-tubulin) caused by NF-κB p65 silencing. CONCLUSION: FLU has a significant anti-migratory effect in intestinal cancer cell SW480 and its lymph node metastatic cells SW620. FLU decreases the expression of some proteins involved in metastatic processes and inhibits activation of NF-κB p65.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035479
003      
CZ-PrNML
005      
20191010103705.0
007      
ta
008      
191007s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.2174/1871520618666171213141911 $2 doi
035    __
$a (PubMed)29237383
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Hanušová, Veronika $u Department of Medical Biology and Genetics, Faculty of Medicine, Charles University in Prague, Simkova 870, Hradec Kralove, CZ-500 38, Czech Republic.
245    14
$a The Effect of Flubendazole on Adhesion and Migration in SW480 and SW620 Colon Cancer Cells / $c V. Hanušová, L. Skálová, V. Králová, P. Matoušková,
520    9_
$a BACKGROUND: Colon cancer is the most common type of gastrointestinal cancer. Despite advances during the last two decades, the efficacy of colorectal cancer treatment is still insufficient and new anticancer agents are necessary. METHODS: In our study, colon cancer cells derived from a primary tumor (SW480) and lymph node metastasis (SW620) from the same patient were used and compared. The effect of flubendazole (FLU) on cell adhesion and migration was monitored using the x-CELLigence Real-Time Cell Analysis system. Expressions of molecules involved in adhesion and migration were analyzed using RT-PCR and western blot. Furthermore, RNA silencing of nuclear factor-κB in SW620 cells was used to determine the involvement of the NF-κB p65 regulation pathway in FLU action. RESULTS: FLU significantly suppressed the adhesion of SW480 cells and reduced the expression of adhesion markers (ICAM-1, αE-catenin; β-catenin; integrin α5 and β1). Moreover, a significant anti-migratory potential of FLU was manifested in the SW620 cells. In addition, FLU suppressed the phosphorylation of NF-κB p65 and potentiated the suppression of several metastatic markers (ICAM-1, EpCAM, integrin α5, β1, α-tubulin) caused by NF-κB p65 silencing. CONCLUSION: FLU has a significant anti-migratory effect in intestinal cancer cell SW480 and its lymph node metastatic cells SW620. FLU decreases the expression of some proteins involved in metastatic processes and inhibits activation of NF-κB p65.
650    _2
$a protinádorové látky $x chemie $x farmakologie $7 D000970
650    _2
$a buněčná adheze $x účinky léků $7 D002448
650    _2
$a pohyb buněk $x účinky léků $7 D002465
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a nádory tračníku $x farmakoterapie $x patologie $7 D003110
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a lidé $7 D006801
650    _2
$a mebendazol $x analogy a deriváty $x chemie $x farmakologie $7 D008463
650    _2
$a molekulární struktura $7 D015394
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Skálová, Lenka $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, Hradec Kralove, CZ-500 05, Czech Republic.
700    1_
$a Králová, Věra $u Department of Medical Biology and Genetics, Faculty of Medicine, Charles University in Prague, Simkova 870, Hradec Kralove, CZ-500 38, Czech Republic.
700    1_
$a Matoušková, Petra $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, Hradec Kralove, CZ-500 05, Czech Republic.
773    0_
$w MED00172590 $t Anti-cancer agents in medicinal chemistry $x 1875-5992 $g Roč. 18, č. 6 (2018), s. 837-846
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29237383 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191010104123 $b ABA008
999    __
$a ok $b bmc $g 1452139 $s 1074029
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 18 $c 6 $d 837-846 $e - $i 1875-5992 $m Anti-cancer agents in medicinal chemistry $n Anticancer Agents Med Chem $x MED00172590
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...